Inovio Pharmaceuticals, Inc. $INO Shares Sold by Stonepine Capital Management LLC

Key Points

• Stonepine Capital Management LLC reduced its stake in Inovio Pharmaceuticals by 50.6%, selling 531,669 shares and retaining approximately 518,331 shares, which now represent 0.8% of its investment portfolio.
• Inovio Pharmaceuticals reported a quarterly loss of ($0.61) EPS, slightly beating analyst expectations of (0.63), with a consensus forecast of -4.23 EPS for the current fiscal year.
• Analysts have differing views on Inovio Pharmaceuticals, with a consensus rating of "Moderate Buy" and a target price of $8.80, despite one firm recently downgrading its rating to "sell."

Stonepine Capital Management LLC trimmed its holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 50.6% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 518,331 shares of the biopharmaceutical company's stock after selling 531,669 shares during the period. Inovio Pharmaceuticals makes up about 0.8% of Stonepine Capital Management LLC's holdings, making the stock its 24th largest holding. Stonepine Capital Management LLC owned approximately 1.41% of Inovio Pharmaceuticals worth $845,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in INO. Alpine Global Management LLC acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at $31,000. Bank of Montreal Can acquired a new stake in shares of Inovio Pharmaceuticals during the 4th quarter worth about $43,000. Boothbay Fund Management LLC purchased a new stake in Inovio Pharmaceuticals in the 4th quarter valued at about $44,000. Barclays PLC raised its holdings in Inovio Pharmaceuticals by 15.0% in the 4th quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 5,111 shares during the period. Finally, Jane Street Group LLC lifted its position in Inovio Pharmaceuticals by 118.2% in the fourth quarter. Jane Street Group LLC now owns 39,704 shares of the biopharmaceutical company's stock valued at $73,000 after buying an additional 21,512 shares during the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on INO. HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Wall Street Zen cut shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Piper Sandler began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They issued an "overweight" rating and a $5.00 target price on the stock. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $5.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. Finally, Oppenheimer decreased their target price on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Inovio Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $8.80.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO traded down $0.11 during mid-day trading on Friday, hitting $2.35. The company had a trading volume of 719,249 shares, compared to its average volume of 1,271,020. The company has a market capitalization of $125.09 million, a PE ratio of -0.90 and a beta of 1.38. Inovio Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $7.55. The business's 50-day simple moving average is $1.67 and its 200 day simple moving average is $1.84.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.02. On average, analysts expect that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.